Vor Biopharma (NYSE:VOR) Receives “Outperform” Rating from Wedbush

Vor Biopharma (NYSE:VOR)‘s stock had its “outperform” rating reiterated by equities research analysts at Wedbush in a report released on Monday,RTT News reports. They presently have a $11.00 price target on the stock.

Other analysts also recently issued reports about the stock. JMP Securities reaffirmed a “market outperform” rating and set a $12.00 price objective on shares of Vor Biopharma in a report on Friday, September 6th. HC Wainwright reaffirmed a “buy” rating and set a $17.50 price target on shares of Vor Biopharma in a research note on Friday, November 8th. Barclays reduced their price objective on Vor Biopharma from $10.00 to $3.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 14th. Finally, Robert W. Baird dropped their target price on Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating for the company in a research report on Friday, November 8th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $11.36.

Vor Biopharma Stock Down 2.9 %

NYSE:VOR opened at $1.01 on Monday. The stock has a market cap of $69.36 million, a P/E ratio of -0.61 and a beta of -0.37. The business’s 50-day moving average price is $0.78 and its two-hundred day moving average price is $0.93. Vor Biopharma has a twelve month low of $0.63 and a twelve month high of $3.14.

Vor Biopharma (NYSE:VOR) last announced its earnings results on Thursday, November 7th. The company reported ($0.40) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.40). On average, equities research analysts expect that Vor Biopharma will post -1.55 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of VOR. Acadian Asset Management LLC raised its holdings in Vor Biopharma by 51.4% during the 2nd quarter. Acadian Asset Management LLC now owns 81,305 shares of the company’s stock valued at $79,000 after buying an additional 27,597 shares during the last quarter. Hsbc Holdings PLC grew its holdings in Vor Biopharma by 177.0% in the 2nd quarter. Hsbc Holdings PLC now owns 49,038 shares of the company’s stock worth $51,000 after acquiring an additional 31,333 shares during the last quarter. Exchange Traded Concepts LLC increased its position in shares of Vor Biopharma by 40.8% in the third quarter. Exchange Traded Concepts LLC now owns 165,805 shares of the company’s stock valued at $116,000 after acquiring an additional 48,017 shares during the period. Cubist Systematic Strategies LLC bought a new position in shares of Vor Biopharma during the second quarter valued at about $53,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Vor Biopharma during the second quarter worth about $63,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.